New citrate solution aims to make kidney dialysis safer for Bleeding-Risk patients

NCT ID NCT05399537

Recruiting now Disease control Sponsor: Vantive Health LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing Prismocitrate 18, a special fluid used during continuous kidney dialysis to prevent blood clots in the dialysis machine. The study will enroll 40 adults with acute kidney injury who need dialysis and cannot use standard blood thinners. Researchers will monitor for dangerous calcium imbalances and citrate buildup over up to 10 days of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Prismocitrate 18 (a citrate-based solution used to prevent blood clotting during kidney dialysis)

What this could lead to

If successful, this could confirm a safer way to prevent blood clots during continuous kidney dialysis, reducing bleeding risks for patients who cannot use standard blood thinners.

What could go wrong

This is a small, early-phase safety study with only 40 participants, so results may not apply to all patients. There are known risks of calcium imbalances (too low or too high) and citrate buildup, which could cause serious symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY (AKI) CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) REGIONAL CITRATE ANTICOAGULATION (RCA)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bon Secours Mercy Health-Springfield Regional Medical Center
RECRUITING

Springfield, Ohio, 45504, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

Contact
Gamma Medical Research, Inc / McAllen Medical Center
ACTIVE_NOT_RECRUITING

McAllen, Texas, 78503, United States
Geisinger Medical Center
NOT_YET_RECRUITING

Danville, Pennsylvania, 17822, United States

Contact

Contact Email: •••••@•••••
Lt. Col. Luke Weathers, Jr. VA Medical Center
RECRUITING

Memphis, Tennessee, 38104, United States

Contact

Contact Email: •••••@•••••
Medical University of South Carolina (MUSC)
NOT_YET_RECRUITING

Charleston, South Carolina, 29425, United States

Contact Email: •••••@•••••

Contact
Methodist Dallas Medical Center
NOT_YET_RECRUITING

Dallas, Texas, 75203, United States

Contact

Contact Email: •••••@•••••
Penn State Hershey Medical Center
WITHDRAWN

Hershey, Pennsylvania, 17033, United States
University of Alabama at Birmingham/UAB
RECRUITING

Birmingham, Alabama, 35294-0007, United States

Contact
University of California Los Angeles
WITHDRAWN

Los Angeles, California, 90095, United States
University of Miami
NOT_YET_RECRUITING

Miami, Florida, 33136, United States

Contact
University of Michigan
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact
University of Southern California (USC) / Keck Hospital
RECRUITING

Los Angeles, California, 90033, United States

Contact Email: •••••@•••••

Contact

Contact Email: •••••@•••••
VA Pittsburgh Healthcare System
ACTIVE_NOT_RECRUITING

Pittsburgh, Pennsylvania, 15240, United States